Cargando…

Pediatric SJS-TEN: Where are we now?

Stevens–Johnson syndrome and toxic epidermal necrolysis are rare severe blistering skin reactions triggered by medications or infections. Over the last 5 to 10 years, a number of important publications have advanced understanding of these diseases and their response to treatment. Importantly, a subs...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramien, Michele, Goldman, Jennifer L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431970/
https://www.ncbi.nlm.nih.gov/pubmed/32850118
http://dx.doi.org/10.12688/f1000research.20419.1
_version_ 1783571692126208000
author Ramien, Michele
Goldman, Jennifer L.
author_facet Ramien, Michele
Goldman, Jennifer L.
author_sort Ramien, Michele
collection PubMed
description Stevens–Johnson syndrome and toxic epidermal necrolysis are rare severe blistering skin reactions triggered by medications or infections. Over the last 5 to 10 years, a number of important publications have advanced understanding of these diseases and their response to treatment. Importantly, a subset of patients with disease triggered by infection has been identified as having Mycoplasma pneumoniae–induced rash and mucositis, suggesting a reconsideration of the diagnostic paradigm. We present an update on pediatric Stevens–Johnson syndrome and toxic epidermal necrolysis in the broader context of cutaneous adverse drug reactions and focus on challenges and recent advances in diagnosis, management, and prevention.
format Online
Article
Text
id pubmed-7431970
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher F1000 Research Limited
record_format MEDLINE/PubMed
spelling pubmed-74319702020-08-25 Pediatric SJS-TEN: Where are we now? Ramien, Michele Goldman, Jennifer L. F1000Res Review Stevens–Johnson syndrome and toxic epidermal necrolysis are rare severe blistering skin reactions triggered by medications or infections. Over the last 5 to 10 years, a number of important publications have advanced understanding of these diseases and their response to treatment. Importantly, a subset of patients with disease triggered by infection has been identified as having Mycoplasma pneumoniae–induced rash and mucositis, suggesting a reconsideration of the diagnostic paradigm. We present an update on pediatric Stevens–Johnson syndrome and toxic epidermal necrolysis in the broader context of cutaneous adverse drug reactions and focus on challenges and recent advances in diagnosis, management, and prevention. F1000 Research Limited 2020-08-13 /pmc/articles/PMC7431970/ /pubmed/32850118 http://dx.doi.org/10.12688/f1000research.20419.1 Text en Copyright: © 2020 Ramien M and Goldman JL http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Ramien, Michele
Goldman, Jennifer L.
Pediatric SJS-TEN: Where are we now?
title Pediatric SJS-TEN: Where are we now?
title_full Pediatric SJS-TEN: Where are we now?
title_fullStr Pediatric SJS-TEN: Where are we now?
title_full_unstemmed Pediatric SJS-TEN: Where are we now?
title_short Pediatric SJS-TEN: Where are we now?
title_sort pediatric sjs-ten: where are we now?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431970/
https://www.ncbi.nlm.nih.gov/pubmed/32850118
http://dx.doi.org/10.12688/f1000research.20419.1
work_keys_str_mv AT ramienmichele pediatricsjstenwherearewenow
AT goldmanjenniferl pediatricsjstenwherearewenow